In line with this model, the OI PLS3 mutations lead to osteoporosis by either (i) directly disrupting the actin-binding site of ABD2 (L478P), (ii) inhibiting the interaction by low, non-inhibitory for WT PLS3, Ca2+ concentrations (N446S, A253_L254insN), or (iii) by disabling the inhibition by physiological Ca2+ concentrations (A368D, E249_A250insI-L). This evidence concerns the gene PLS3 and osteoporosis.